Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How the Change in Reasonable Suspicion Policies Could Impact Employers

Reasonable suspicion for drug testing on the job changed recently under the new administration. To cover what’s new and provide tips for employers, Safety Justice League welcomed Adele Abrams, an attorney focusing on OSHA (Occupational Safety and Health Administration), MSHA (Mine Safety and Health Administration), and employee safety. “Reasonable suspicion is a hot topic again under a new…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Reasonable suspicion for drug testing on the job changed recently under the new administration. To cover what’s new and provide tips for employers, Safety Justice League welcomed Adele Abrams, an attorney focusing on OSHA (Occupational Safety and Health Administration), MSHA (Mine Safety and Health Administration), and employee safety.

“Reasonable suspicion is a hot topic again under a new administration focused more on workers. It’s a hybrid issue—a little bit HR, safety, and DOT,” Abrams explained.

In 2016, the rules of testing post-injury had to include reasonable suspicion that the cause of it was drug-related. Failure to show this, and the employer could face fines. If found to be wrongfully tested, workers could be reinstated and receive back pay and benefits.

That practice ended during the Trump administration, allowing drug testing after an incident as long as it was part of a root cause investigation. Under Biden, the policy shifts back to the 2016 stance.

“OSHA is now looking at from the worker’s perspective. Prior, there was elimination of worker protections. Employers need to change their policy, or they can risk complaints,” Abrams said.

Abrams noted that whistleblowing could also apply to those making safety complaints. “If an employee makes a safety complaint, and they require a test, which is negative, the worker is protected. Even supervisors can face fines.”

Abrams’ advice to employers is to “be as objective as you can to avoid litigation.” Unfortunately, reasonable suspicion itself lends itself to being more subjective. “You can use a checklist to note what you’re observing about demeanor, appearance, and behavior. But you’ll need to apply it a meaningful way, which means knowing your workers and their normal behavior.”

Psychological Health: The Often Hidden Side of Supporting a Healthy Workplace

How to Keep Safety First During a Skilled Labor Shortage

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation in US manufacturing lags, with 80% of factories lacking automation tools. In contrast, medtech manufacturers are advancing with technologies like micro-molding and ultrasonic welding. This disparity highlights a growing gap in technology adoption across different sectors.

  • 0180% of US factories have no automation.
  • 02Medtech manufacturers are investing in automation technologies.
  • 03There's an increasing divide in technology adoption across industries.

Jul 12, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512